Alpha 2.0
Login Register
» Articles » PMID: 11726840

Two Doses of Daclizumab Are Sufficient for Prolonged Interleukin-2Ralpha Chain Blockade

Overview
Journal Transplantation
Specialty General Surgery
Date 2001 Dec 1
PMID 11726840
Citations 4
Authors
C G Ter Meulen
C C Baan
R J Hene
L B Hilbrands
A J Hoitsma
Affiliations
Soon will be listed here.
Citing Articles

Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period.

Zivcic-Cosic S, Lisjak J, Racki S, Trobonjaca Z Int Urol Nephrol. 2013; 46(1):191-200.

PMID: 23515930 DOI: 10.1007/s11255-013-0413-3.

Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.

Sageshima J, Ciancio G, Chen L, Burke 3rd G Biologics. 2009; 3:319-36.

PMID: 19707418 PMC: 2726067. DOI: 10.2147/btt.2009.3257.

Induction therapy in renal transplantation : an overview of current developments.

Ciancio G, Burke G, Miller J Drugs. 2007; 67(18):2667-80.

PMID: 18062717 DOI: 10.2165/00003495-200767180-00003.

Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?.

van Gelder T, Warle M, Ter Meulen R Drugs. 2004; 64(16):1737-41.

PMID: 15301558 DOI: 10.2165/00003495-200464160-00001.